Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
Disease
73%
Hodgkin's Lymphoma
56%
Drug Megadose
53%
Diffuse Large B-Cell Lymphoma
45%
Bone Marrow Transplantation
42%
Overall Survival
39%
Peripheral T-Cell Lymphoma
32%
Transplantation
30%
Neoplasm
29%
Autologous Bone Marrow Transplantation
28%
Malignant Neoplasm
25%
High Dose Chemotherapy
25%
B Cell
23%
Follicular Lymphoma
21%
Autologous Hematopoietic Stem Cell Transplantation
20%
Autotransplantation
20%
Cyclophosphamide
20%
Large-Cell Lymphoma
18%
Lymphoma
18%
Rituximab
17%
Mantle Cell Lymphoma
17%
Autograft
16%
Cancer
15%
Autologous Stem Cell Transplantation
15%
Stem Cell
15%
International Prognostic Index
15%
Acute Myeloid Leukemia
14%
Radiation Therapy
14%
Doxorubicin
14%
T Cell
14%
Failure Free Survival
14%
Clinical Trial
13%
Vincristine
13%
Granulocyte Macrophage Colony Stimulating Factor
13%
Positron Emission Tomography
12%
Event Free Survival
12%
Patient with Non-Hodgkins Lymphoma
11%
B-Cell Lymphoma
11%
B-Cell Chronic Lymphocytic Leukemia
11%
Multivariate Analysis
11%
Peripheral Stem Cell Transplantation
11%
Disease Free Survival
11%
Prognostic Factor
11%
Prednisone
11%
CHOP
10%
Histiocytic Lymphoma
10%
Whole Body Radiation
10%
Chemotherapy Regimens
10%
Hemopoietic Growth Factor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
59%
Chemotherapy
47%
Disease
37%
Remission
36%
Hodgkin Disease
30%
High Dose Chemotherapy
25%
Overall Survival
21%
Cyclophosphamide
18%
Diffuse Large B Cell Lymphoma
15%
Doxorubicin
15%
Neoplasm
15%
Prednisone
14%
Malignant Neoplasm
13%
Vincristine
13%
Lymphoma
13%
Acute Myeloid Leukemia
13%
Clinical Trial
13%
Large Cell Lymphoma
12%
Follicular Lymphoma
11%
Rituximab
10%
Peripheral T Cell Lymphoma
9%
Granulocyte Macrophage Colony Stimulating Factor
9%
Failure Free Survival
8%
Event Free Survival
8%
Disease Free Survival
8%
Survival Rate
8%
Hemopoietic Growth Factor
8%
Acute Leukemia
8%
Phase I Trials
7%
Histiocytic Lymphoma
7%
Granulocyte Colony Stimulating Factor
7%
Cytarabine
7%
Anthracycline
6%
Mantle Cell Lymphoma
6%
Progression Free Survival
6%
Myelodysplastic Syndrome
6%
Etoposide
5%
Chemotherapy Regimens
5%
Hematologic Malignancy
5%
Leukemia
5%
Procarbazine
5%
Growth Factor
5%
Clinical Feature
5%
Keyphrases
Non-Hodgkin Lymphoma
43%
Lymphoma
38%
Diffuse Large B-cell Lymphoma (DLBCL)
27%
Allogeneic Bone Marrow Transplantation
26%
Hodgkin Disease
25%
Bone Marrow Transplantation
24%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
22%
Chemotherapy
20%
High-dose Therapy
18%
High-dose Chemotherapy
17%
Complete Remission
16%
Peripheral T-cell Lymphoma
15%
Overall Survival
14%
Follicular Lymphoma
12%
Transplantation
12%
Nebraska
9%
Bone Marrow
9%
Acute Myeloid Leukemia
9%
Prednisone
8%
Autologous Transplantation
8%
Mantle Cell Lymphoma
8%
Remission
8%
Marrow Transplantation
8%
Autotransplant
7%
Hodgkin Lymphoma
7%
Granulocyte Colony-stimulating Factor (G-CSF)
7%
Hematopoietic Growth Factors
7%
Disease-free Survival
7%
Histiocytic Lymphoma
7%
Chemotherapy Regimen
7%
International Prognostic Index
6%
T-cell Lymphoma
6%
Initial Treatment
6%
North America
6%
Relapsed Lymphoma
6%
Confidence Interval
6%
Event-free Survival
5%
Doxorubicin
5%
Failure-free Survival
5%
Hematological Malignancies
5%
Marrow
5%
Autologous Blood
5%
Aggressive Lymphoma
5%
Cyclophosphamide
5%
Treatment Outcome
5%
Survival Outcomes
5%
Lymphoid Malignancies
5%
Malignancy
5%